Mirum Pharmaceuticals Inc. (MIRM)
Factsheet
-
Market Capitalisation
$1,040 Mln
-
-
Price to Earnings Ratio
--
-
12 Month Earnings
$-129 Mln
Mirum Pharmaceuticals Inc. (MIRM) Share Price
NASDAQ
$31.58
As on 06-Dec-2023 16:00 EST
$-0.92
•
-2.83%
As on 06-Dec-2023 16:00 EST
-
Prev Close
$32.50
-
Day's Open
$32.40
-
Today's High
$32.83
-
Today's Low
$31.56
-
Today's Volume
347,280
-
52 Week range
$17.49 - 33.39
Please wait...
Mirum Pharmaceuticals Inc. (MIRM) Stock Performance
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mirum Pharmaceuticals (MIRM)
| 61.95 | 5.27 | 14.34 | 72.29 | 9.58 | -- | -- |
|
S&P BSE Sensex*
| 14.36 | 7.11 | 5.61 | 11.10 | 15.57 | 14.53 | 12.73 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
As on 06-Dec-2023
| *As on 07-Dec-2023 | #As on 26-Oct-2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|
|
Mirum Pharmaceuticals (MIRM)
| 22.26 | -8.65 | -28.79 |
|
S&P Small-Cap 600
| -17.42 | 25.27 | 9.57 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 |
Valuation
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Growth & Efficiency
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Solvency
Is there a threat to this company's solvency in the future?
Financial Manipulation
Can creative accounting be detected through the financial numbers?
Mirum Pharmaceuticals Inc. (MIRM) Peer Comparison
Please wait...
Valuation Chart of Mirum Pharmaceuticals Inc. (MIRM)
Please wait...
Please wait...
Financials
Please wait...
Please wait...
Please wait...
Shareholding Pattern
Other details of Mirum Pharmaceuticals Inc. (MIRM)
Pres, CEO & Director
Mr. Christopher Peetz
Chief Financial Officer
Dr. Ian Clements
Headquarters
Foster City, CAWebsite
https://www.mirumpharma.comFAQs for Mirum Pharmaceuticals Inc. (MIRM)
What is the total asset value of Mirum Pharmaceuticals Inc. (MIRM)?
The total asset value of Mirum Pharmaceuticals Inc. (MIRM) stood at $ 382 Mln as on 31-Mar-23
What is the current share price of Mirum Pharmaceuticals Inc. (MIRM)?
The share price of Mirum Pharmaceuticals Inc. (MIRM) is $31.58 (NASDAQ) as of 06-Dec-2023 16:00 EST. Mirum Pharmaceuticals Inc. (MIRM) has given a return of 9.58% in the last 3 years.
What is the market cap of Mirum Pharmaceuticals Inc. (MIRM)?
Mirum Pharmaceuticals Inc. (MIRM) has a market capitalisation of $ 1,040 Mln as on 23-Jun-2023. As per Value Research classification, it is a Small Cap company.
What is the current PB ratio of Mirum Pharmaceuticals Inc. (MIRM)?
The P/B ratio of Mirum Pharmaceuticals Inc. (MIRM) is 3.96 times as on 23-Jun-2023, a 0.56% premium to its peers’ median range of 2.54 times.
What is the current P/E ratio of Mirum Pharmaceuticals Inc. (MIRM)?
Since, TTM earnings of Mirum Pharmaceuticals Inc. (MIRM) is negative, P/E ratio is not available.
How can you buy shares of Mirum Pharmaceuticals Inc. (MIRM)?
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mirum Pharmaceuticals Inc. (MIRM) and enter the required number of quantities and click on buy to purchase the shares of Mirum Pharmaceuticals Inc. (MIRM).
What is the main business of Mirum Pharmaceuticals Inc. (MIRM)?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Who are the promoters/managers of Mirum Pharmaceuticals Inc. (MIRM)?
The CEO & director of Mr. Christopher Peetz. is Mirum Pharmaceuticals Inc. (MIRM), and CFO & Sr. VP is Dr. Ian Clements.
What is the total promoter pledging in Mirum Pharmaceuticals Inc. (MIRM)?
The promoters of Mirum Pharmaceuticals Inc. (MIRM) have pledged 0% of the total equity as on Mar-23.
Who are the competitors of Mirum Pharmaceuticals Inc. (MIRM)?
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
132
|
|
|
104
|
|
|
83
|
|
|
81
|
What are the key ratios of Mirum Pharmaceuticals Inc. (MIRM)?
| Mirum Pharmaceuticals Inc. (MIRM) | Ratios |
|---|---|
|
Return on equity(%)
|
-83.23
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
Is the Mirum Pharmaceuticals Inc. (MIRM) profitable?
No, TTM profit after tax of Mirum Pharmaceuticals Inc. (MIRM) was $-129 Mln.
Edit
Please wait...
Please wait...
Key Facts
-
Market cap
$1,040.17 Mln
-
Revenue (TTM)
$95.77 Mln
-
Earnings (TTM)
$-129.19 Mln
-
Cash
$132.07 Mln
-
Total Debt
$1.97 Mln
- Insider's Holding 3.78%
-
Liquidity
High
-
52 Week range
$17.49 - 33.39
-
Shares outstanding
38,031,800
-
5 Years Aggregate:
CFO: $-381.89 Mln
EBITDA: $-349.32 Mln
Net Profit: $-392.82 Mln
About The Company
- IPO Date 18-Jul-2019
- Pres, CEO & Director Mr. Christopher Peetz
- Chief Financial Officer Dr. Ian Clements
-
Listing
NASDAQ: MIRM
- Country United States
-
Headquarters
Foster City, CA
-
Website
https://www.mirumpharma.com
-
Business
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug... for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California. Read more
